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We thank Vega-Morales et al (ref) for their interest in our proposed approach for identifying 
individuals at-risk of rheumatoid arthritis (RA) in a primary care setting [1,2]. The authors 
agree that primary care is usually the first point of contact for RA patients when they initially 
develop symptoms. For this reason, they agree that general practitioners (GPs) are well 
placed to be involved in screening strategies to identify individuals at risk of progressing to 
RA (ref). 
Vega-Morales et al advocate the squeeze test (Gaenslen ?s compression test) as a screening 
tool to aid GPs in identifying at risk individuals for onward referral to a rheumatologist. The 
rationale for the squeeze test is that compression of the MCP joints evokes pain in an 
individual with active synovitis. We agree that the squeeze test is useful for identifying early 
arthritis [3], but its sensitivity is limited and it may need to be combined with other 
screening tests in order to be sufficiently discriminatory [4]. Nonetheless it is cheap, quick 
and easy to perform and therefore an appropriate test for the GP who suspects a patient 
may have developed RA. Automation of the squeeze test, as proposed by Vega-Morales et 
al, may indeed have a role in this setting (ref). Whether the squeeze test is sensitive enough 
to identify subclinical synovitis detected by ultrasound will be an important question to 
address.     
Despite its use in early arthritis, we would argue that the squeeze test is inappropriate for 
identifying at risk individuals, including those with imminent, but not yet established, 
synovitis. This important group, who have risk factors for RA (including systemic 
autoimmunity) but crucially do not have arthritis, must be identified before synovitis 
develops in order to benefit from potential preventative intervention. In line with this, the 
EULAR taskforce definition for arthralgia suspicious for progression to RA is aimed at 
identifying homogeneous patient groups that are at risk of developing arthritis before they 
progress to RA [5]. 
Testing for anti-CCP antibodies in individuals who present to their GP with a new 
musculoskeletal complaint can effectively identify individuals at high risk of developing RA, 
before the onset of synovitis, and without the need for specialist assessment [2]. In those 
that have a positive anti-CCP test, further risk assessment using clinical, serological and 
imaging tests can then quantify the risk of progression to arthritis more accurately [6]. Thus 
at risk individuals may be followed in longitudinal studies and further stratified for risk 
appropriate intervention. The cost-effectiveness of this approach will need to be 
determined, but must be considered in the correct context; it may be a key advance toward 
preventing a disease that is associated with considerable morbidity, treatment and societal 
costs (7).  
Vega-DŽƌĂůĞƐĞƚĂů ?s response highlights the changing paradigm of early RA. The concept of 
early disease is changing from early arthritis to pre-arthritis while the target changes from 
early remission to prevention. As such, novel screening approaches are required. These 
must effectively identify at risk individuals prior to the onset of synovitis for bone fide 
prevention to be feasible.    
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